Neurocrine Biosciences Inc (NBIX)

Operating profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Operating income (ttm)	US$ in thousands	570,500	578,800	536,200	464,400	250,900	204,000	150,600	131,700	249,000	109,300	66,000	74,100	102,500	210,600	121,800	135,600	163,000	140,000	274,400	232,200
Revenue (ttm)	US$ in thousands	2,355,300	2,241,400	2,117,000	1,978,200	1,882,900	1,779,300	1,668,300	1,522,900	1,411,600	1,306,100	1,208,800	1,185,500	1,107,700	1,050,200	1,010,800	1,022,200	1,020,900	1,017,010	981,066	862,604
Operating profit margin		24.22%	25.82%	25.33%	23.48%	13.33%	11.47%	9.03%	8.65%	17.64%	8.37%	5.46%	6.25%	9.25%	20.05%	12.05%	13.27%	15.97%	13.77%	27.97%	26.92%

December 31, 2024 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $570,500K ÷ $2,355,300K
= 24.22%

Neurocrine Biosciences Inc's operating profit margin has shown fluctuations over the periods analyzed. The company's operating profit margin ranged from a low of 5.46% in June 30, 2022, to a high of 27.97% in June 30, 2020. The operating profit margin dropped significantly in the later periods of 2021 and early 2022, hitting a low of 5.46% in June 30, 2022. However, the margin recovered gradually and showed an upward trend in the subsequent periods, reaching 25.82% in September 30, 2024, before slightly decreasing to 24.22% by December 31, 2024.

Overall, the operating profit margin of Neurocrine Biosciences Inc reflects some variability, with periods of both decline and improvement. It is important for the company to closely monitor and manage its operating expenses and revenues to ensure sustainable profitability and stability in the future.